AI-generated · cited to primary sources · not investment advice
Sai Life (544306) Nov 2025 Filing Analysis
Where does growth come from?
The company is maintaining a heavy investment cycle, with H1 FY26 capex already at ₹248 crores against a full-year plan of ₹700 crores, indicating a steady execution of infrastructure build-out. (1 steady, 1 accelerating across 2 signals)
“We incurred a capex of around INR 248 crores for the first half, against a plan of INR700 crores for the entire FY26.”
See the full cited Future Growth analysis of Sai Life
What could break the thesis?
The risk is EASING as the company is successfully diversifying its client base. They now report 300+ active customers, including 18 of the top 25 global pharma companies, and are expanding into new modalities to attract a broader range of clients. (2 easing, 1 stable)
“300+ Active customers across US, UK, EU, Japan... 18/25 of the largest pharmaceutical companies are customers”
Management explicitly stated they see no material impact from innovator companies investing in the US. Customers are primarily looking to do final formulation in the US, while continuing to source advanced intermediates and APIs from India. (3 stable, 1 easing)
“Explicitly, the answer is no... They only want to do the final two stages in the US in formulation. They say advanced intermediates, RSMs, no impact... I don't see any material impact.”
See the full cited Risk analysis of Sai Life
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.